DK1268509T3 - Type 2 isoformer af sphingosin-kinase fra pattedyr, kloning, ekspression og fremgangsmåder til anvendelse deraf - Google Patents
Type 2 isoformer af sphingosin-kinase fra pattedyr, kloning, ekspression og fremgangsmåder til anvendelse derafInfo
- Publication number
- DK1268509T3 DK1268509T3 DK01924340.1T DK01924340T DK1268509T3 DK 1268509 T3 DK1268509 T3 DK 1268509T3 DK 01924340 T DK01924340 T DK 01924340T DK 1268509 T3 DK1268509 T3 DK 1268509T3
- Authority
- DK
- Denmark
- Prior art keywords
- cloning
- expression
- methods
- type
- sphingosine kinase
- Prior art date
Links
- ZDRVLAOYDGQLFI-UHFFFAOYSA-N 4-[[4-(4-chlorophenyl)-1,3-thiazol-2-yl]amino]phenol;hydrochloride Chemical compound Cl.C1=CC(O)=CC=C1NC1=NC(C=2C=CC(Cl)=CC=2)=CS1 ZDRVLAOYDGQLFI-UHFFFAOYSA-N 0.000 title 1
- 102000001708 Protein Isoforms Human genes 0.000 title 1
- 108010029485 Protein Isoforms Proteins 0.000 title 1
- 238000010367 cloning Methods 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 108010035597 sphingosine kinase Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/52—Genes encoding for enzymes or proenzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/91—Transferases (2.)
- G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- G01N2333/91205—Phosphotransferases in general
- G01N2333/9121—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Cardiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Plant Pathology (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Hospice & Palliative Care (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US19431800P | 2000-04-03 | 2000-04-03 | |
| US09/817,676 US6800470B2 (en) | 2000-04-03 | 2001-03-26 | Mammalian sphingosine kinase type 2 isoforms, cloning, expression and methods of use thereof |
| PCT/US2001/009664 WO2001074837A1 (en) | 2000-04-03 | 2001-03-26 | Mammalian sphingosine kinase type 2 isoforms, cloning, expression and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1268509T3 true DK1268509T3 (da) | 2010-03-08 |
Family
ID=26889896
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK01924340.1T DK1268509T3 (da) | 2000-04-03 | 2001-03-26 | Type 2 isoformer af sphingosin-kinase fra pattedyr, kloning, ekspression og fremgangsmåder til anvendelse deraf |
Country Status (9)
| Country | Link |
|---|---|
| US (4) | US6800470B2 (enExample) |
| JP (1) | JP4584525B2 (enExample) |
| KR (1) | KR20020093017A (enExample) |
| AU (1) | AU5100201A (enExample) |
| CA (1) | CA2404965A1 (enExample) |
| DK (1) | DK1268509T3 (enExample) |
| HU (1) | HUP0301691A3 (enExample) |
| MX (1) | MXPA02009781A (enExample) |
| WO (1) | WO2001074837A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1268509T3 (da) * | 2000-04-03 | 2010-03-08 | Daiichi Sankyo Co Ltd | Type 2 isoformer af sphingosin-kinase fra pattedyr, kloning, ekspression og fremgangsmåder til anvendelse deraf |
| AUPQ744700A0 (en) * | 2000-05-11 | 2000-06-01 | Medvet Science Pty. Ltd. | A method of treatment and agents useful for same |
| JP2005522999A (ja) * | 2002-01-31 | 2005-08-04 | ミレニアム・ファーマシューティカルズ・インコーポレイテッド | 癌を処置するための方法および組成物 |
| WO2004035786A1 (en) * | 2002-10-14 | 2004-04-29 | Medvet Science Pty. Ltd. | A method of modulating epithelial cell activity by modulating the functional levels of sphingosine kinase |
| AU2003292636A1 (en) * | 2002-12-27 | 2004-07-29 | The New Industry Research Organization | Cell growth inhibitor using sphingosine kinase 2, method of constructing fused protein having its nuclear localization signal, method of screening drug candidate, and screening kit |
| US8372888B2 (en) * | 2008-04-29 | 2013-02-12 | Enzo Therapeutics, Inc. | Sphingosine kinase type 1 inhibitors, compositions and processes for using same |
| US8314151B2 (en) | 2008-04-29 | 2012-11-20 | Enzo Therapeutics, Inc. | Sphingosine kinase type 1 inhibitors, and processes for using same |
| US10660879B2 (en) | 2017-06-23 | 2020-05-26 | Enzo Biochem, Inc. | Sphingosine pathway modulating compounds for the treatment of cancers |
| US10675255B2 (en) | 2017-06-23 | 2020-06-09 | Enzo Bochem, Inc. | Sphingosine pathway modulating compounds for the treatment of cancers |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5374616A (en) * | 1991-10-18 | 1994-12-20 | Georgetown University | Compositions containing sphingosylphosphorylcholine and the use thereof as a cellular growth factor |
| AU4097999A (en) * | 1998-05-26 | 1999-12-13 | Sarah Spiegel | Sphingosine kinase, cloning, expression and methods of use |
| AU3828301A (en) * | 2000-02-14 | 2001-08-27 | Curagen Corp | Novel sphingosine kinases |
| DK1268509T3 (da) * | 2000-04-03 | 2010-03-08 | Daiichi Sankyo Co Ltd | Type 2 isoformer af sphingosin-kinase fra pattedyr, kloning, ekspression og fremgangsmåder til anvendelse deraf |
-
2001
- 2001-03-26 DK DK01924340.1T patent/DK1268509T3/da active
- 2001-03-26 KR KR1020027013149A patent/KR20020093017A/ko not_active Withdrawn
- 2001-03-26 AU AU5100201A patent/AU5100201A/xx active Pending
- 2001-03-26 HU HU0301691A patent/HUP0301691A3/hu unknown
- 2001-03-26 US US09/817,676 patent/US6800470B2/en not_active Expired - Fee Related
- 2001-03-26 JP JP2001572526A patent/JP4584525B2/ja not_active Expired - Fee Related
- 2001-03-26 MX MXPA02009781A patent/MXPA02009781A/es unknown
- 2001-03-26 WO PCT/US2001/009664 patent/WO2001074837A1/en not_active Ceased
- 2001-03-26 CA CA002404965A patent/CA2404965A1/en not_active Abandoned
-
2004
- 2004-04-22 US US10/830,677 patent/US7419814B2/en not_active Expired - Fee Related
-
2007
- 2007-08-14 US US11/891,964 patent/US7803595B2/en not_active Expired - Fee Related
-
2010
- 2010-07-27 US US12/804,664 patent/US8263349B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US7419814B2 (en) | 2008-09-02 |
| US6800470B2 (en) | 2004-10-05 |
| US7803595B2 (en) | 2010-09-28 |
| CA2404965A1 (en) | 2001-10-11 |
| JP2004500117A (ja) | 2004-01-08 |
| JP4584525B2 (ja) | 2010-11-24 |
| US20120107833A1 (en) | 2012-05-03 |
| US20020042101A1 (en) | 2002-04-11 |
| KR20020093017A (ko) | 2002-12-12 |
| MXPA02009781A (es) | 2004-09-06 |
| US20040203104A1 (en) | 2004-10-14 |
| US8263349B2 (en) | 2012-09-11 |
| US20090169555A1 (en) | 2009-07-02 |
| WO2001074837A1 (en) | 2001-10-11 |
| AU5100201A (en) | 2001-10-15 |
| HUP0301691A2 (hu) | 2003-08-28 |
| HUP0301691A3 (en) | 2005-04-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK199900234U4 (da) | Paroxetin-methansulfonat i krystallinsk form, farmaceutisk præparat indeholdende dette og andvendelse af forbindelsen til f | |
| DK1268431T3 (da) | 3-Cyanoquinoliner, 3-cyano-1,6-naphthyridiner og 3-cyano-1,7-naphthyridiner som proteinkinaseinhibitorer | |
| DK1133477T3 (da) | Substituerede benzimidazoler og deres anvendelse som parpinhibitorer | |
| NO20012158D0 (no) | Substituerte 2-fenylbenzimidazoler, fremgangsmåte til fremstilling og anvendelse derav | |
| NO20021449L (no) | Substituerte 2-tio-3,5-dicyano-4-aryl-6-aminopyridiner og deres anvendelse | |
| NO20032830D0 (no) | Tetrahydropyridinderivater, fremstilling derav og anvendelse som celle-proliferasjonsinhibitorer | |
| NO20005454L (no) | Nye hydroksyindoler, deres anvendelse som fosfodiesterase 4 inhibitorer og fremgangsmåte for fremstilling derav | |
| NO20024742L (no) | Heterocykliske forbindelser, deres fremstilling og anvendelse | |
| ATE258928T1 (de) | Respiratorisches syncytialvirus replikation inhibitoren | |
| NO20031952L (no) | 3-aroylinderivater og deres anvendelse som CB2 reseptoragonister | |
| NO20032797L (no) | Substituerte pyridoindoler som serotonin agonister og antagonister | |
| ATE259796T1 (de) | Respiratorisches syncytialvirus replikation inhibitoren | |
| DK1339292T3 (da) | Sammensætning og fremgangsmåde | |
| DK1265482T3 (da) | Vandige formulationer og fremgangsmåde til fremstilling af samme | |
| NO20024201D0 (no) | Substituerte 3-fenyl-5-alkoksy-1,3,4-oksdiazol-2-on og anvendelse derav for hemning av hormonsensitiv lipase | |
| DK1261697T3 (da) | Kuldeaktiv beta-galactosidase, fremgangsmåde til fremstilling heraf og anvendelsen deraf | |
| NO995513D0 (no) | N-triazolyl-2-indolkarboksamider og deres anvendelse som CCK-A agonister | |
| NO20030848D0 (no) | Paroxetinsammensetninger og fremgangsmåter for å lage det samme | |
| DK1268509T3 (da) | Type 2 isoformer af sphingosin-kinase fra pattedyr, kloning, ekspression og fremgangsmåder til anvendelse deraf | |
| NO20034434D0 (no) | Indolinoner substituert i 6-stilling og deres anvendelse som kinase-inhibitorer | |
| NO20026103L (no) | 1-amino-alkylcycloheksaner som 5-HT3 og neuronale nikotinreseptorantagonister | |
| NO20004144D0 (no) | Heterocykliske forbindelser, deres fremstilling og anvendelse som takykinin reseptor antagonister | |
| DK1214302T3 (da) | Substituerede 3-phenyl-5-alkoxy-1,3,4-oxadiazol-2-oner og deres anvendelse som lipasehæmmere | |
| NO20030998D0 (no) | Arylpiperazinderivater og deres anvendelse som psykotropiske midler | |
| NO20022969D0 (no) | Sammensetninger og metoder for L-nukleosider, L-nukleotider og analoger derav |